Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Adding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according to EHA Congress data.

Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

2025 ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become more widely used.

Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

Hope S. Rugo, MD, FASCO, emphasized the importance of educating patients about proactive rash and diarrhea management while taking PI3K/AKT inhibitors.

Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer

Paolo Tarantino, MD, PhD, explains that the chemotherapy-related toxicities from an ADC are more likely to limit dosage for patients with cancer.

Understanding How On-Target and Off-Target ADC Toxicities Work

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

From All Angles

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Danielle Saff, LCSW, OSW-C, is an oncology social worker at Cancer

Bridget Hoyt is the assistant editor for Oncology Nursing News. She earned her BA in communication studies at Rider University with a minor in public relations. She can be reached at 

Explore essential mental health support strategies for older adults with cancer, addressing grief, community resources, and tailored care approaches.

Supporting Mental Health and Autonomy for Older Adults With Cancer

Amanda Brink is a nurse practitioner at the University of Texas MD Anderson Cancer Center. When she is not tending to patients in the hospital or clinic, she finds great satisfaction in crafting content to enlighten the public and her fellow nurses about a range of health topics.

Oncology nurses can ensure patients with non–small cell lung cancer receive the optimal treatment quickly by understanding comprehensive genomic profiling.

Opinion: Comprehensive Genomic Profiling Is Vital for Optimizing NSCLC Care

Gina Mauro currently serves as Vice President of Content at MJH Life Sciences, overseeing 

®. Gina joined the company in 2015 and has held various positions on 

Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News – Clinical Insights for Cancer Care Nurses

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

March was National Kidney Month, so here is an opportunity to test your knowledge about kidney cancer.

Myths and Facts About Kidney Cancer

Help kidney cancer patients by being aware of available resources and support services

Resources for People Living with Kidney Cancer

Behavioral therapy reduced episodes of urinary incontinence following radical prostatectomy by 55% in a study of 208 men with incontinence persisting %u22651 year following prostatectomy.

Behavioral Therapy Alleviates Prostatectomy-Induced Incontinence

, we ring in the New Year 2023 by combing through 2022 FDA approvals. Listen as associate editor, Lindsay Fischer, recounts key approvals on a month-by-month basis, with input from some of the investigators from behind the research. To read the full information surrounding the approvals, be sure to check out our news coverage below. Other resources can also be found below.

, and for all the engagement in 2022. We look forward to bringing you more oncology news in 2023.

We want to hear from you! Which drugs approved in 2022 have been practice changing? Have you had any difficulty or success in incorporating these novel agents into clinical use? Any challenges with supporting patients on these regimens? Email 

FDA Approves Tebentafusp to Treat HLA-A*02:01 Positive Uveal Melanoma

Cilta-Cel Snags FDA Approval for Relapsed/Refractory Multiple Myeloma

Neoadjuvant Nivolumab Plus Platinum-Doublet Chemotherapy Is Now Approved for Resectable NSCLC

FDA Greenlights Olaparib for BRCA-Mutated, HER2-Negative Breast Cancer

FDA OKs Relatlimab/Nivolumab for Unresectable or Metastatic Melanoma

FDA Approves Pembrolizumab in MSI H/dMMR Advanced Endometrial Carcinoma

FDA Approves 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Axi-Cel Snags FDA Approval for Second-Line LBCL

FDA Approves Trastuzumab Deruxtecan for Unresectable or Metastatic HER2+ Breast Cancer

FDA Grants Ivosidenib Plus Azacitidine Approval for Newly Diagnosed AML With IDH1 Mutations

FDA Grants Azacitidine Approval For Pediatric Patients With Myelomonocytic Leukemia

FDA Grants 2 Frontline Nivolumab-Based Regimens Approval for Unresectable Advanced or Metastatic ESCC

Tisagenlecleucel Receives FDA Approval for Relapsed or Refractory Follicular Lymphoma

FDA Grants Accelerated Approval to Dabrafenib Plus Trametinib for BRAF V600E–Mutated Solid Tumors

FDA Approves Liso-Cel for Second-Line Large B-Cell Lymphoma

Crizotinib Approved For ALK+ Inflammatory Myofibroblastic Tumors

HER2-Directed Therapy, Trastuzumab Deruxtecan, Approved for Metastatic NSCLC

Trastuzumab Deruxtecan Is Approved for Patients With Metastatic HER2-Low Breast Cancer

FDA Approves Darolutamide Tablets for Select Patients With Prostate Cancer

Capmatinib Snags Full FDA Approval for MET Exon 14 Skipping NSCLC

FDA Grants Ibrutinib Approval for Pediatric Graft-Versus-Host-Disease

FDA Gives Pemigatinib Greenlight for FGFR1 Rearranged Myeloid/Lymphoid Neoplasms

Durvalumab Plus Gemcitabine/Cisplatin Approved by the FDA for Advanced or Metastatic Biliary Tract Cancers

Sodium Thiosulfate Gets Green Light for Chemotherapy-Induced Hearing Loss in Pediatric Patients

Selpercatinib Is Approved for 2 RET Fusion–Positive Solid Tumors, Non–Small Cell Lung Cancer

FDA Approves Futibatinib for Pretreated, Advanced or Metastatic Intrahepatic Cholangiocarcinoma with FGFR2 Rearrangements

FDA Approves Durvalumab in Combination with Tremelimumab for Unresectable HCC

Teclistamab-cqyv Snags Accelerated Approval for Relapsed or Refractory Multiple Myeloma

Cemiplimab Gets Go Ahead In Combination With Chemotherapy For Advanced NSCLC

Brentuximab Vedotin Gets Green Light for High-Risk Hodgkin Lymphoma in Pediatric Patients

Durvalumab/Tremelimumab/Chemotherapy Combination Approved for NSCLC Indication

Mirvetuximab Soravtansine-gynx Gets Go Ahead in Platinum-Resistant Ovarian Cancer

Olutasidenib Approved for IDH1-Mutated Acute Myeloid Leukemia

Adagrasib Receives Accelerated Approval for KRAS G12C Mutated NSCLC

Watch: Newly Approved Tebentafusp Requires Up-Front Active Toxicity Management in Melanoma

Dr. Geyer Highlights Optimal Dosing Strategies for New Olaparib Indication in Breast Cancer

Nurse Takeaways: Latest Pembrolizumab Indication in Endometrial Cancer

Podsada Discusses Biomarker Testing and ADC Therapies in Breast Cancer

Goodwin Provides Nursing Perspective on Recent FDA Approvals in NSCLC

Futibatinib Approval Ushers in Targeted Therapy Option for Patients With Unresectable, Intrahepatic FGFR2-Positive Cholangiocarcinoma

Barber Discusses the Integration of Durvalumab/Chemotherapy Combination as New Standard of Care in Biliary Tract Cancers

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.  

A Look Back at 2022 FDA Approvals in Oncology

® met with Lidia Schapira, MD, FASCO, to discuss key advances in the treatment of toxicities that may present later in cancer survivorship care.

Schapira is a professor of medicine and director of the Cancer Survivorship Program at Stanford. Schapira specializes in breast cancer with a focus on the psychosocial aspects of cancer care and issues that relate to patient experience and health equity. She recently participated in a poster discussion in the Symptoms and Survivorship track at the 2022 

Schapira discusses recent innovation in addressing later toxicities in survivorship care. She highlights the importance of baseline measurements and health equity considerations in clinical practice and underscores the potential effect evolving technologies may have on the treatment landscape.

“The idea that we can [provide] certain interventions that help people with cognitive reframing and psychoeducation—delivered in their own time, without the need of a specialist—[is] very powerful,” Schapira said. “If we add up all the possible physical, psychological, emotional toxicities of cancer treatments, we come up with a large burden, not to even mention the financial hardship that many of the patients endure as well.”

, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms, to get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care. 

Key Advances in Cancer Survivorship Toxicity Management

® spoke with Hamid Emamekhoo, MD, an assistant professor of the Division of Hematology, Medical Oncology and Palliative Care with the University of Wisconsin Carbone Cancer Center. Emamekhoo offers a snapshot of recent advances in kidney cancer treatments, an overview of caring for patients receiving immunotherapy and TKI combinations, and where future advances for kidney cancer research are headed.

“We have used high dose interleukin-2 for the treatment of kidney cancer since 1992—we have been doing immunotherapy for kidney cancer before immunotherapy was cool. But it was not the best treatment modality because it is a little hard to tolerate. It causes a lot of side effects because it mimics a severe sepsis and riles up the immune system,” explains Emamekhoo. “Of course, with the advancements in immunotherapy [and with] the approvals of [various] immune checkpoint inhibitors, that has changed significantly.”

Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. 

. 2007;13(5):1367-1373. doi:10.1158/1078-0432.CCR-06-2328.

Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. 

. 1995;13:688-696. doi:10.1200/JCO.1995.13.3.688.

Tung I, Sahu A. Immune checkpoint inhibitor in first-line treatment of metastatic renal cell carcinoma: a review of current evidence and future directions. 

 2021(11):707214. doi:10.3389/fonc.2021.707214.

FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma. FDA. News release. April 16, 2018. Accessed March 23, 2022. https://bit.ly/37Wi3Uz

FDA approves Merck’s Keytruda (pembrolizumab) in combination with Inlyta (axitinib) as first-line treatment for patients with advanced renal cell carcinoma (RCC). Merck. April 22, 2019. Accessed April 22, 2019. https://bit.ly/2IKrjMM

FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma. FDA. News release. January 1, 2021. Accessed March 23, 2022. 

FDA approves KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) combination for first-line treatment of adult patients with advanced renal cell carcinoma (RCC). News release. Merck. August 11, 2021. Accessed March 23, 2022. 

AVEO Oncology Announces U.S. FDA Approval of FOTIVDA® (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma. AVEO Oncology. News release. March 10, 2021. Accessed March 10, 2021. 

FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma. FDA. News release. November 17, 2021. Accessed March 23, 2022. 

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma

Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. 

Cella D, Choueiri TK, Hamilton M, et al. Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: five-year follow-up results. 

. 2022;40(suppl 6):307. doi:10.1200/JCO.2022.40.6_suppl.307

Choi WSW, Boland J, Lin J. Hypoxia-Inducible Factor-2α as a Novel Target in Renal Cell Carcinoma. 

. 2021;8(2):1-7. doi:10.15586/jkcvhl.v8i1.170

FDA approves belzutifan for cancers associated with von Hippel-Lindau disease. FDA. News release. Accessed August 13, 2021. 

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease?utm_medium=email&utm_source=govdelivery

In this episode of “The Vitals,” Hamid Emamekhoo, MD, discusses the evolving treatment landscape of kidney cancer. 

Carbone Cancer Center Expert Shares Biggest Updates in Kidney Cancer Treatment

Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.

KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC

A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, MD, PhD.

Neoantigen Vaccine Shows Promise in Mutated Renal Cell Carcinoma

Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during cisplatin therapy.

Opinion: IV Magnesium May Help Prevent Cisplatin-Induced AKI

Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane chemotherapy.

Ga-68 Kit Approved for Pre-Taxane RLT Selection in mCRPC

Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.

Genitourinary Cancer

Latest News

More News

Latest Conference Coverage